Kura Oncology CSO Sells 1,311 Shares to Cover RSU Taxes; Company Posts Commercial Milestone
Kura Oncology Chief Scientific Officer Francis Burrows sold 1,311 shares on Jan. 27, 2026, at $8.4607 per share to satisfy tax obligations tied to an RSU vesting. The company meanwhile reported its first U.S. commercial sale of KOMZIFTI, triggering a $135 million milestone payment from partner Kyowa Kirin expected before the end of 2025.